Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer.

BACKGROUND: Osteoprotegerin (OPG) is a tumour and/or bone derived factor that may protect tumour cells from apoptosis. In this study, we have measured serum OPG levels in untreated prostate cancer patients with advanced prostate cancer compared to patients with organ confined disease and in treated...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Eaton, C, Wells, J, Holen, I, Croucher, P, Hamdy, F
Μορφή:	Journal article
Γλώσσα:	English
Έκδοση:	2004

Παρόμοια τεκμήρια

Serum osteoprotegerin (OPG) levels and disease progression in prostate cancer patients
ανά: Eaton, C, κ.ά.
Έκδοση: (2004)

Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells.
ανά: Holen, I, κ.ά.
Έκδοση: (2002)

Osteoprotegerin is an anti-apoptotic factor produced by prostate cancer cells that is potentially involved in tumour survival and progression.
ανά: Holen, I, κ.ά.
Έκδοση: (2002)

Role of osteoprotegerin (OPG) in cancer.
ανά: Holen, I, κ.ά.
Έκδοση: (2006)

The role of osteoprotegerin in breast and prostate cancer
ανά: Holen, I, κ.ά.
Έκδοση: (2002)

OPG is a survival factor for breast- and prostate cancer cells in vitro
ανά: Holen, I, κ.ά.
Έκδοση: (2002)

Polymorphisms within the osteoprotegerin (OPG) gene are associated with both serum OPG levels and bone mineral density.
ανά: Miles, L, κ.ά.
Έκδοση: (2004)

Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome
ανά: Gamal B Mohamed, κ.ά.
Έκδοση: (2011-01-01)

Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact
ανά: Holen Ingunn, κ.ά.
Έκδοση: (2009-07-01)

Role of Osteoprotegerin (OPG) in Bone Marrow Adipogenesis
ανά: Lili Zhang, κ.ά.
Έκδοση: (2016-11-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
ανά: Riham Eid, κ.ά.
Έκδοση: (2023-06-01)

Significant Inverse Correlation of Serum Levels of Osteoprotegerin (OPG) and Transferrin Saturation in Thalassemia Dependent Transfusion (TDT) Patients
ανά: Indra Wijaya, κ.ά.
Έκδοση: (2024-01-01)

Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma.
ανά: Croucher, P, κ.ά.
Έκδοση: (2000)

Effect of Ibandronate Therapy on Serum Chemerin, Vaspin, Omentin-1 and Osteoprotegerin (OPG) in Postmenopausal Osteoporotic Females
ανά: Saba Tariq, κ.ά.
Έκδοση: (2022-02-01)

Myeloma cells can down-regulate release of osteoprotegerin (OPG) from human bone cells - A contributing factor in myeloma bone loss?
ανά: Shipman, C, κ.ά.
Έκδοση: (2002)

Serum proinflammatory cytokines, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG) and RANKL/OPG ratio in mild and severe COVID-19
ανά: Siamak Kazemi-Sufi, κ.ά.
Έκδοση: (2024-09-01)

Myeloma cells isolated from patients with multiple myeloma express osteoprotegerin ligand.
ανά: Shipman, C, κ.ά.
Έκδοση: (2000)

Osteoprotegerin (OPG) is a soluble decoy receptor for TRAIL/Apo2L and can inhibit TRAIL/Apo2L-induced apoptosis of human myeloma cells in vitro.
ανά: Shipman, C, κ.ά.
Έκδοση: (2002)

Endogenous osteoprotegerin (OPG) represses ERα and promotes stemness and chemoresistance in breast cancer cells
ανά: Noura N. Alraouji, κ.ά.
Έκδοση: (2024-08-01)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
ανά: Chan Kai-Ming, κ.ά.
Έκδοση: (2011-07-01)

Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease
ανά: Syed Muhammad Muneeb Akhtar, κ.ά.
Έκδοση: (2024-07-01)

The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers.
ανά: Waterman, E, κ.ά.
Έκδοση: (2007)

Effect of androgen deprivation therapy on serum levels of sclerostin, Dickkopf-1, and osteoprotegerin: a cross-sectional and longitudinal analysis
ανά: Alice Wang, κ.ά.
Έκδοση: (2021-07-01)

Analysis of periodontal parameteres and salivary levels of Receptor Activator of NF- κβ Ligand (RANKL) and Osteoprotegerin (OPG) in obese periodontitis patients
ανά: Cheema, Raheem Ramzan
Έκδοση: (2021)

Effects of osteoprotegerin from transfection of pcDNA3.1(+)/chOPG on bioactivity of chicken osteoclasts
ανά: Yao Jing, κ.ά.
Έκδοση: (2011-03-01)

Changes of serum osteoprotegerin level in recurrent urolithiasis
ανά: A. V. Savilov, κ.ά.
Έκδοση: (2023-10-01)

Can androgen receptor levels in the prostate predict non-organ-confined prostate cancer?
ανά: Hamdy, F
Έκδοση: (2005)

Osteoprotegerin and the development of myeloma bone disease
ανά: Croucher, P, κ.ά.
Έκδοση: (2004)

Dickkopf-1 levels and serum Osteoprotegerin in women with Osteoporosis
ανά: Mehrzad Hajialilo, κ.ά.
Έκδοση: (2013-12-01)

Serum levels of OPG, RANKL and RANKL/OPG ratios in newly-diagnosed patients with multiple myeloma. Clinical correlations
ανά: Veselina Goranova-Marinova, κ.ά.
Έκδοση: (2007-07-01)

Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers
ανά: Martin Widschwendter, κ.ά.
Έκδοση: (2015-10-01)

Enhancing androgen ablation response in metastatic hormone-sensitive prostate cancer: the benefits of transurethral resection of the prostate
ανά: Yan Zhao, κ.ά.
Έκδοση: (2023-07-01)

Rapid Androgen-Responsive Proteome Is Involved in Prostate Cancer Progression
ανά: Jong-Kwang Kim, κ.ά.
Έκδοση: (2021-12-01)

The influence of vitamin D administration on the clinical presentation, body mass index, and osteoprotegerin (OPG) level in a sample of Egyptian children with familial Mediterranean fever
ανά: Hanaa Reyad Abdallah, κ.ά.
Έκδοση: (2021-12-01)

Osteoprotegerin, sclerostin, and osteocalcin serum levels in thyroid disorder patients
ανά: F. F. Rija, κ.ά.
Έκδοση: (2021-10-01)

Serum Osteoprotegerin Levels and the Vascular Reactivity Index in Patients with Hypertension
ανά: Yen-Liang Chen, κ.ά.
Έκδοση: (2023-10-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
ανά: Yosra Azizpour, κ.ά.
Έκδοση: (2020-01-01)

Investigation of the effect of hydroalcoholic mumie extract on expression of osteoprotegerin (OPG) and receptor activator of nuclear factor kappa-B ligand (RANKL)
ανά: Yosra Azizpour, κ.ά.
Έκδοση: (2020-01-01)

Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease.
ανά: Croucher, P, κ.ά.
Έκδοση: (2003)

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma.
ανά: Croucher, P, κ.ά.
Έκδοση: (2001)